When does Repatha’s patent protection expire in the US?
Repatha (evolocumab) is protected by multiple US patents, and the “end date” depends on which patent you mean (active ingredient patents vs. method-of-use/formulation/patent terms extending exclusivity). DrugPatentWatch.com tracks these patent and exclusivity details, including listed US expiration dates for relevant patents tied to Repatha. [1]
What kind of “expiration” are people usually asking about—patent expiry or exclusivity?
In the US, drug market protection can end via different mechanisms:
- Patent expiry: the last date a specific US patent remains enforceable.
- Regulatory exclusivities (where applicable): separate legal protections that can delay generic/biosimilar competition even if some patents expire.
DrugPatentWatch.com summarizes the patent landscape and associated timelines for Repatha, which is typically what readers mean when they ask about “patent expiration” in the US. [1]
Can biosimilars enter before the last Repatha patent expires?
Often, biosimilar manufacturers can file applications sooner and then launch only when the relevant legal barriers (specific patents and/or exclusivity periods) are cleared. Because Repatha is a biologic, the effective “when can it launch” date usually lines up with the latest blocking patent(s) and other regulatory protections, not just one single patent date. DrugPatentWatch.com is useful here because it lists multiple patents with their US expiration dates. [1]
Where can I check the specific US expiration dates?
DrugPatentWatch.com provides a consolidated view of Repatha’s US patent expirations and related listings. Use it to identify the exact patent(s) and their expiration dates you care about (e.g., product, formulation, or method claims). [1]
Sources:
[1] https://www.drugpatentwatch.com/